


**Supplementary figures and tables**

**IL-7 receptor blockade blunts antigen-specific memory T cell responses and  
chronic inflammation in primates**

by Belarif et al.


**Supplementary Figure 1: *In vitro* functional characterization of anti-IL7R $\alpha$  mAbs.**

(A) *Left*: Representative phosphorylated STAT5 (pSTAT5) staining by flow cytometry of unstimulated baboon PBMCs or incubated 15min with 0.1ng/ml of human IL-7  $\pm$  10 $\mu$ g/ml of anti-IL7R $\alpha$  mAbs. *Right*: IL-7-induced pSTAT5 inhibition with increasing concentration of site-1/2b IgG4 mAb (blue), site-1/2b IgG1 mAb (red), site-1 IgG4 (green) mAbs, or Ig control (grey). (B) TSLP-induced CCL17 secretion (normalized to control condition without mAb) by CD1c<sup>+</sup> dendritic cells with increasing concentration of anti-IL7R $\alpha$  mAbs (same colors as in (A)) or anti-TSLPR mAb (black). (C) *Left*: Specific cytotoxicity (%) induced by anti-IL7R $\alpha$  mAbs (same colors as in (A)) on transfected IL-7R $\alpha$ <sup>+</sup> Ba/F3 cell line cultured 4 hours with NK cells (ratio 1:10). *Right*: Specific cytotoxicity (%) induced with increasing concentration of site-1/2b IgG1 on human T cell leukemia expressing high level of CD127 (DND-41 cell line, solid red line) or low level of CD127 (Jurkat cell line, dotted red line) cultured 4 hours with NK cells (ratio 1:10). Data are mean  $\pm$  SEM.




**Supplementary Figure 2: Pharmacological evaluation following intravenous administration of anti-IL7R $\alpha$  mAbs in baboons.**

(A) Total CD127 expression represented by the Mean Fluorescence Intensity (MFI) measured by flow cytometry on peripheral blood CD3<sup>+</sup> baboon T lymphocytes after a single intravenous injection of 10mg/kg of the site-1/2b IgG1 mAb (red, n = 3), site-1/2b IgG4 mAb (blue, n = 3) or site-1 IgG4 mAb (green, n = 3). Dotted line represents the mean basal level of expression before administration of mAbs. (B) Serum concentration of anti-IL7R $\alpha$  mAbs after injection in same animals as in (A). (C) CD127 receptor occupancy determined by flow cytometry on peripheral CD3<sup>+</sup> T lymphocytes purified from the blood (*left*) or lymph nodes (*right*) of the same animals as in (A). Data are mean  $\pm$  SEM.




**Supplementary Figure 3: Sheep red blood cell (SRBC) immunization.**

(A) Anti-SRBC IgG fold-change serum titers in baboons treated with a single intravenous injection of 10mg/kg of the site-1/2b IgG1 mAb (red, n = 3), site-1/2b IgG4 mAb (blue, n = 3) or site-1 IgG4 mAb (green, n = 3), and challenged 24 hours later with intravenous injection of 1.5ml/kg of SRBC at 10%. Historical placebo-treated animals (black, n = 3) following the same protocol were used as controls <sup>50</sup>. (B) Same as in (A) after secondary SRBC challenge performed 20 weeks following anti-IL7R $\alpha$  mAb administration. Data are mean  $\pm$  SEM. \* p<0.05 one-way ANOVA and Dunn's test comparison between the site1/2b IgG4 mAb and control group at 2 weeks post-SRBC challenge.




**Supplementary Figure 4: Anti-IL-7R $\alpha$  mAbs in primates do not induce modification of peripheral blood cells.**

Peripheral blood immune cell enumeration and T cell subset frequency determined by flow cytometry for baboons treated with a single intravenous injection of 10mg/kg of the site-1/2b IgG1 mAb (red, n= 3), site-1/2b IgG4 mAb (blue, n = 3) or site-1 IgG4 mAb (green, n = 3). T cell sub-populations were defined using the following gating strategy CD3<sup>+</sup> CD4<sup>+</sup> or CD8<sup>+</sup> cells for Tem: effector memory T cells (CD95<sup>+</sup> CD28<sup>-</sup>), Tcm: central memory T cells (CD95<sup>+</sup> CD28<sup>+</sup>), Tn: naïve T cells (CD95<sup>-</sup> CD28<sup>+</sup>), Tregs: regulatory T cells (CD4<sup>+</sup> CD25<sup>high</sup> Foxp3<sup>+</sup>) as previously described <sup>76</sup>. Data are mean  $\pm$  SEM of the indicated population.




**Supplementary Figure 5: Anti-IL7R $\alpha$  mAb administration does not induce significant peripheral cytokine release.**

Serum concentration (pg/mL) of indicated cytokines (IL-2, IL-4, IL-5, IL-6, TNF $\alpha$  and INF $\gamma$ ) in baboons after a single intravenous injection of 10mg/kg of the site-1/2b IgG1 mAb (red, n= 3), site-1/2b IgG4 mAb (blue, n = 3) or site-1 IgG4 mAb (green, n = 3). Data are mean  $\pm$  SEM.




**Supplementary Figure 6: Comparison of anti-IL-7R $\alpha$  site-1 and site1/2b mAbs agonist signals on human cell by western blot.**

Raw data of the representative phospho-STAT5, phospho-PI3k-p55, phospho-ERK1/2 and GAPDH western blot of one out of seven representative human donor cells illustrated in Figure 3C. PBMCs were pretreated with 10 $\mu$ g/mL of one anti-IL-7R $\alpha$  mAb and then incubated for 10 min at 37 $^{\circ}$ C with or without 5ng/ml of human IL-7.




**Supplementary Figure 7: Comparison of anti-IL-7R $\alpha$  site-1 and site1/2b mAbs agonist signals on human and baboon PBMC.**

Phospho-STAT5, phospho-PI3k-p55, phospho-ERK1/2 and GAPDH western blot on human (A) or baboon cells (B). PBMCs were pretreated with 10 $\mu$ g/mL of anti-IL-7R $\alpha$  mAbs (Site 1/2b IgG4, Site 1/2b IgG1, Site 1 IgG4 #1, Site 1 IgG1 #1, Site 1 IgG1 #2 and Site 1 IgG4 #3) or human isotype control (Iso hIgG4 and Iso hIgG1) and then incubated for 10 min at 37°C before protein lysates analysis.






**Supplementary Figure 8: Gene Ontology (GO) identified in the signature for each anti-IL-7R $\alpha$  mAb (blue: site-1/2b IgG4, red: site-1 IgG4#1, green: site-1 IgG1#2) versus control. Circle size is proportional to the number of genes for each category.**




**Supplementary Figure 9: GoMiner gene ontology enrichment of the three clusters identified for the 93 most differentially expressed genes (FDR 5%, FC > 2) between IL-7 stimulation and control medium condition.**




**Supplementary Figure 10: IKZF4 gene expression.**

IKZF4 mRNA expression confirmed by RT-qPCR on human PBMC cultured for 3.5 hours with (empty round) or without (full symbols) 5 ng/ml of IL-7 and 10  $\mu$ g/ml of anti-human IL-7R $\alpha$  mAbs (blue: site-1/2b IgG4, red: site-1 IgG4#1, green: site-1 IgG1#2). Data were normalized to basal expression in the absence of IL-7 and mAbs. \*  $p < 0.05$  between indicated groups.




**Supplementary Figure 11: Erythema and Elispot response in the non-responder animal.**

Cutaneous erythema response (black histograms, *left-axis*) at indicated time-points, represented with area under the curve (AUC) of daily erythema diameters, after tuberculin intradermal injection in the non-responder baboon (1 out of 10) treated with a single intravenous injection of 10mg/Kg of the humanized site-1/2b IgG4 mAb. IFN- $\gamma$ -secreting cell frequencies (white histograms, *right-axis*) in PBMCs of the same animal after *ex-vivo* tuberculin restimulation at the indicated time-point.



**Supplementary Figure 12: CD25 and C69 expression on baboon CD3<sup>+</sup> T cells population before and after stimulation.**

Representative expression of CD25 and CD69 analyzed by flow cytometry on peripheral blood T-cell (CD3<sup>+</sup>) at the indicated time-point after treatment with a single intravenous injection of 10 mg/kg of a humanized site-1/2b IgG4 mAb. CD25 and CD69 expression was analyzed on T cells in unstimulated or after 48 hours of anti-CD3 polyclonal stimulation.



**Supplementary Table 1: List of genes significantly (FDR 5%) and differentially (fold-change >1.5) expressed after incubation of human PBMCs (n=7) with anti-IL7R $\alpha$  mAbs compared to unstimulated cells.**

Gene	Site 1/2b IgG4			Site 1 IgG4 #1			Site 1 IgG1 #2			EMC8			FAM115C				
	log <sub>2</sub> (U/instim. adj.P.Val)	Differential		log <sub>2</sub> (U/instim. adj.P.Val)	Differential		log <sub>2</sub> (U/instim. adj.P.Val)	Differential		0.61	0.229	1.15	0.004	*	1.04	0.008	*
ACADVL	0.85	0.040	*	1.15	0.001	*	0.87	0.011	*	0.37	0.264	0.61	0.022	*	0.64	0.013	*
AHR	0.86	0.029	*	1.16	0.000	*	1.21	0.000	*	-0.35	0.234	-0.59	0.011	*	-0.66	0.004	*
AKIRIN1	0.75	0.028	*	0.88	0.002	*	0.78	0.006	*	-0.48	0.188	-0.67	0.023	*	-0.85	0.003	*
ALDH16A1	1.23	0.021	*	1.45	0.001	*	1.32	0.003	*	0.55	0.076	0.78	0.002	*	0.70	0.005	*
ALDH5A1	0.72	0.044	*	0.93	0.002	*	1.05	0.001	*	0.82	0.073	0.92	0.016	*	0.95	0.010	*
APPBP2	0.81	0.001	*	0.90	0.000	*	0.81	0.000	*	0.70	0.087	1.05	0.002	*	0.80	0.014	*
ARHGAP1	0.85	0.001	*	1.05	0.000	*	0.88	0.000	*	0.43	0.280	0.74	0.019	*	0.74	0.017	*
B3GNT2	1.03	0.034	*	1.23	0.003	*	1.15	0.005	*	0.97	0.056	1.05	0.014	*	0.84	0.047	*
C17orf59	1.07	0.039	*	1.49	0.001	*	1.27	0.004	*	0.42	0.287	0.77	0.013	*	0.77	0.010	*
CDC117	0.77	0.024	*	0.88	0.002	*	0.80	0.005	*	0.54	0.088	0.61	0.019	*	0.59	0.022	*
CCNI	0.73	0.004	*	0.98	0.000	*	0.78	0.001	*	0.58	0.165	0.74	0.028	*	0.90	0.006	*
CDK17	0.98	0.003	*	1.09	0.000	*	0.94	0.001	*	0.38	0.344	0.86	0.005	*	0.67	0.028	*
COTL1	1.67	0.000	*	1.80	0.000	*	1.35	0.000	*	0.63	0.116	0.81	0.013	*	0.96	0.042	*
CYP11B1	-0.66	0.029	*	-0.75	0.003	*	-0.69	0.006	*	0.54	0.149	0.71	0.019	*	0.62	0.040	*
DDI2	1.17	0.011	*	1.45	0.000	*	1.24	0.002	*	0.45	0.248	0.92	0.003	*	0.82	0.007	*
DEF6	1.03	0.030	*	1.39	0.001	*	1.09	0.006	*	0.86	0.161	1.54	0.002	*	1.38	0.005	*
DNIL2	1.17	0.029	*	1.19	0.008	*	1.22	0.006	*	0.54	0.249	0.81	0.029	*	1.19	0.001	*
DUSP2	1.73	0.002	*	2.18	0.000	*	2.30	0.000	*	0.49	0.263	0.77	0.030	*	1.70	0.044	*
ENG	-0.73	0.004	*	-0.61	0.005	*	-0.67	0.002	*	1.05	0.089	-1.24	0.015	*	-1.06	0.036	*
EXOC2	0.69	0.043	*	0.52	0.033	*	0.63	0.016	*	0.89	0.112	0.93	0.047	*	0.75	0.006	*
FAM160B1	0.83	0.030	*	1.26	0.000	*	0.72	0.024	*	0.69	0.150	1.05	0.007	*	0.90	0.017	*
FEM1B	0.99	0.005	*	1.09	0.000	*	0.87	0.005	*	-0.32	0.298	-0.61	0.013	*	-0.61	0.010	*
GCF2	1.00	0.011	*	0.87	0.011	*	0.83	0.013	*	0.20	0.700	0.79	0.021	*	0.83	0.012	*
GNAS1	0.99	0.011	*	1.14	0.001	*	1.25	0.000	*	0.52	0.086	0.97	0.000	*	0.79	0.002	*
GOPC	0.83	0.015	*	0.64	0.029	*	0.69	0.015	*	0.41	0.212	0.52	0.018	*	0.61	0.017	*
GRIFF1	0.65	0.015	*	0.81	0.000	*	0.69	0.002	*	0.65	0.089	-0.73	0.022	*	-0.62	0.028	*
HIPK3	0.67	0.025	*	0.79	0.002	*	0.69	0.006	*	0.74	0.067	0.92	0.006	*	0.72	0.028	*
HMHA1	0.88	0.004	*	1.05	0.000	*	0.89	0.001	*	0.22	0.633	0.63	0.046	*	0.69	0.022	*
HSPB11	1.04	0.029	*	0.97	0.017	*	0.86	0.030	*	0.58	0.173	0.80	0.020	*	0.74	0.028	*
JUNB	0.91	0.025	*	1.25	0.000	*	1.42	0.000	*	0.56	0.095	0.67	0.016	*	0.66	0.014	*
KLC2	1.08	0.036	*	1.18	0.007	*	1.34	0.002	*	0.60	0.077	0.69	0.016	*	0.69	0.012	*
LYSMD2	0.78	0.016	*	0.72	0.010	*	0.70	0.009	*	0.39	0.408	-1.89	0.049	*	-1.41	0.008	*
LYZ	-0.60	0.031	*	-0.86	0.000	*	-0.76	0.001	*	1.02	0.125	1.19	0.049	*	1.15	0.009	*
MS4A7	-0.80	0.001	*	-0.98	0.000	*	-0.59	0.006	*	0.84	0.031	0.84	0.031	*	1.00	0.008	*
MTA2	0.84	0.038	*	1.18	0.001	*	1.10	0.002	*	0.39	0.408	0.77	0.032	*	1.13	0.002	*
NCOA5	0.65	0.018	*	0.84	0.000	*	0.89	0.000	*	0.44	0.204	0.69	0.012	*	0.72	0.007	*
NSUN2	0.63	0.029	*	0.74	0.002	*	0.75	0.002	*	-0.01	0.992	0.71	0.021	*	0.74	0.013	*
PITH1	0.81	0.040	*	1.03	0.002	*	0.81	0.013	*	0.51	0.283	0.75	0.047	*	0.83	0.024	*
PLEKHF2	0.72	0.004	*	0.83	0.000	*	0.77	0.001	*	0.24	0.595	0.76	0.014	*	0.66	0.030	*
POLR1MT	1.09	0.001	*	1.30	0.000	*	1.06	0.000	*	0.66	0.068	0.63	0.040	*	0.99	0.001	*
PPP2CA	0.75	0.025	*	0.87	0.002	*	0.75	0.007	*	0.96	0.180	1.17	0.044	*	1.22	0.031	*
PREB	0.88	0.018	*	0.78	0.014	*	0.92	0.004	*	0.96	0.180	-0.53	0.102	*	-0.62	0.017	*
PRKCH	0.70	0.011	*	0.88	0.000	*	0.78	0.001	*	0.68	0.096	0.77	0.024	*	0.98	0.003	*
PSMD3	1.01	0.035	*	1.58	0.000	*	1.37	0.001	*	0.95	0.092	1.23	0.008	*	1.22	0.007	*
PYGO2	1.08	0.003	*	1.07	0.001	*	0.74	0.016	*	0.79	0.069	1.15	0.001	*	1.15	0.002	*
RAG5	0.63	0.004	*	0.67	0.000	*	0.60	0.002	*	0.51	0.208	0.72	0.026	*	0.82	0.009	*
RBL2	0.71	0.011	*	0.85	0.000	*	0.59	0.012	*	0.23	0.751	0.97	0.034	*	1.15	0.009	*
RRP1	0.69	0.019	*	0.62	0.013	*	0.80	0.002	*	0.66	0.052	0.78	0.006	*	0.67	0.016	*
SMCHD1	0.71	0.001	*	1.00	0.000	*	0.85	0.000	*	0.47	0.137	0.65	0.011	*	0.61	0.014	*
SREBF2	0.83	0.009	*	1.13	0.000	*	0.98	0.000	*	0.91	0.076	1.22	0.004	*	1.17	0.005	*
TAF11	1.87	0.001	*	1.57	0.001	*	1.28	0.006	*	0.64	0.145	0.90	0.012	*	0.72	0.044	*
TAF4B	0.75	0.030	*	1.12	0.000	*	1.29	0.000	*	0.50	0.145	0.82	0.003	*	0.76	0.005	*
TMA4	1.04	0.009	*	1.13	0.001	*	0.89	0.009	*	0.56	0.054	0.71	0.003	*	0.64	0.007	*
TPOX1	2.55	0.008	*	2.96	0.000	*	2.06	0.011	*	0.47	0.242	0.85	0.007	*	0.65	0.038	*
TRAM1	0.71	0.001	*	0.73	0.000	*	0.59	0.002	*	0.51	0.220	0.86	0.008	*	0.83	0.009	*
TRPC4AP	0.98	0.005	*	1.21	0.000	*	1.06	0.001	*	0.80	0.061	1.09	0.002	*	0.75	0.033	*
TTCL3	0.76	0.034	*	0.90	0.003	*	0.68	0.022	*	-0.43	0.034	-0.49	0.005	*	-0.63	0.000	*
UNC119	1.02	0.036	*	1.43	0.001	*	1.26	0.002	*	-0.45	0.041	-0.43	0.022	*	-0.61	0.001	*
USP9K	0.90	0.000	*	0.92	0.000	*	0.85	0.000	*	-0.56	0.040	-0.61	0.008	*	-0.48	0.036	*
VP54A	0.74	0.042	*	0.95	0.002	*	0.75	0.012	*	0.64	0.028	0.64	0.001	*	0.55	0.004	*
ZNF800	0.74	0.013	*	1.01	0.000	*	0.84	0.001	*	-0.49	0.004	-0.62	0.004	*	-0.35	0.013	*
ACTN4	0.55	0.005	*	0.60	0.000	*	0.65	0.000	*	-0.36	0.046	-0.38	0.013	*	-0.75	0.000	*
C15orf48	-0.63	0.029	*	-0.87	0.000	*	-0.51	0.035	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
C3AR1	-0.56	0.011	*	-0.75	0.000	*	-0.64	0.001	*	-0.52	0.040	-0.66	0.002	*	-0.42	0.051	*
CD247	0.80	0.004	*	0.87	0.000	*	0.50	0.038	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
FAM50A	0.66	0.028	*	0.93	0.000	*	0.54	0.031	*	-0.52	0.040	-0.66	0.002	*	-0.42	0.051	*
HCK	-0.65	0.009	*	-0.83	0.000	*	-0.46	0.030	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
IL6ST	0.43	0.034	*	0.60	0.000	*	0.77	0.000	*	-0.52	0.040	-0.66	0.002	*	-0.42	0.051	*
JAK1	0.71	0.001	*	0.80	0.000	*	0.58	0.002	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
KYNU	-0.60	0.018	*	-0.94	0.000	*	-0.56	0.007	*	-0.52	0.040	-0.66	0.002	*	-0.42	0.051	*
NCF2	-0.57	0.029	*	-0.71	0.001	*	-0.70	0.001	*	-0.55	0.034	-0.60	0.006	*	-0.38	0.091	*
PAPF10	0.58	0.037	*	0.75	0.002	*	0.73	0.002	*	-0.48	0.034	-0.60	0.002	*	-0.36	0.846	*
RAD51L2	0.61	0.037	*	0.66	0.008	*	0.53	0.033	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
SMG5	0.54	0.033	*	0.80	0.000	*	0.75	0.001	*	-0.52	0.040	-0.66	0.002	*	-0.42	0.051	*
TOR3A	0.73	0.028	*	0.62	0.028	*	0.57	0.040	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
ADM	-0.88	0.005	*	-1.01	0.000	*	-0.02	0.967	*	-0.52	0.040	-0.66	0.002	*	-0.42	0.051	*
CES1	-0.77	0.028	*	-0.78	0.008	*	-0.45	0.145	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
SLC31A2	-0.79	0.004	*	-0.60	0.012	*	-0.17	0.577	*	-0.52	0.040	-0.66	0.002	*	-0.42	0.051	*
SMPL3A	-1.11	0.009	*	-1.12	0.002	*	-0.56	0.149	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
TREM1	-0.72	0.009	*	-0.67	0.005	*	-0.28	0.287	*	-0.52	0.040	-0.66	0.002	*	-0.42	0.051	*
VNN1	-0.97	0.030	*	-1.17	0.002	*	-0.35	0.423	*	0.49	0.040	0.74	0.000	*	0.49	0.013	*
FLT1	-1.01	0.028	*	-0.													

COMMD8	-0.33	0.165	-0.59	0.002	-0.40	0.034	VNN2	-0.47	0.086	-0.60	0.008	-0.41	0.074
CPD	0.52	0.055	0.46	0.043	0.64	0.004	WBP5	0.25	0.205	-0.42	0.020	-0.70	0.238
CYSR1	-0.25	0.227	-0.51	0.011	-0.72	0.000	WPT	0.78	0.061	0.78	0.026	0.57	0.108
DUSP6	-0.45	0.129	-0.61	0.013	-0.48	0.049	ZDHHC3	0.56	0.095	0.73	0.008	0.30	0.328
ENY2	-0.45	0.067	-0.46	0.026	-0.59	0.004	ZHR1	0.58	0.161	0.78	0.019	0.36	0.333
FCER1G	-0.45	0.165	-0.75	0.004	-0.51	0.049	ZNF589	0.27	0.504	0.73	0.012	0.25	0.474
FRMD8	0.52	0.053	0.72	0.001	0.49	0.028	ZNF71	0.11	0.101	0.65	0.020	0.23	0.487
GR	0.43	0.086	0.71	0.001	0.50	0.014	ZNF792	0.70	0.108	0.95	0.008	0.67	0.673
KIF1B	0.45	0.092	0.59	0.007	0.57	0.008	ZNF800	0.27	0.108	0.95	0.008	0.67	0.673
KIF2D	0.53	0.103	0.60	0.028	0.57	0.035	ZNF801	0.27	0.108	0.95	0.008	0.67	0.673
MP11	0.38	0.220	0.58	0.020	0.75	0.002	ZNF802	0.27	0.108	0.95	0.008	0.67	0.673
MRP9	-0.43	0.075	-0.55	0.006	-0.68	0.000	ZNF803	0.27	0.108	0.95	0.008	0.67	0.673
NDUF45	-0.25	0.247	-0.60	0.000	-0.36	0.037	ZNF804	0.27	0.108	0.95	0.008	0.67	0.673
NDUF87	-0.37	0.213	-0.49	0.043	-0.62	0.007	ZNF805	0.27	0.108	0.95	0.008	0.67	0.673
NUP153	0.34	0.228	0.57	0.009	0.62	0.005	ZNF806	0.27	0.108	0.95	0.008	0.67	0.673
SD004	-0.41	0.120	-0.54	0.014	-0.82	0.000	ZNF807	0.27	0.108	0.95	0.008	0.67	0.673
SD008	-0.38	0.266	-0.56	0.043	-0.77	0.004	ZNF808	0.27	0.108	0.95	0.008	0.67	0.673
SEIPN1A1	-0.46	0.067	-0.69	0.001	-0.47	0.021	ZNF809	0.27	0.108	0.95	0.008	0.67	0.673
SLC17A5	-0.33	0.173	-0.51	0.010	-0.72	0.000	ZNF810	0.27	0.108	0.95	0.008	0.67	0.673
SLC7A7	-0.47	0.076	-0.68	0.002	-0.52	0.016	ZNF811	0.27	0.108	0.95	0.008	0.67	0.673
SNRK-AS1	0.59	0.079	0.57	0.042	0.59	0.031	ZNF812	0.27	0.108	0.95	0.008	0.67	0.673
STAT3A	0.34	0.166	0.66	0.001	0.49	0.012	ZNF813	0.27	0.108	0.95	0.008	0.67	0.673
TBXAS1	-0.27	0.290	-0.49	0.043	-0.64	0.007	ZNF814	0.27	0.108	0.95	0.008	0.67	0.673
TFPI2	-0.52	0.079	-0.65	0.008	-0.49	0.042	ZNF815	0.27	0.108	0.95	0.008	0.67	0.673
TMEM184B	0.22	0.545	0.63	0.013	0.55	0.027	ZNF816	0.27	0.108	0.95	0.008	0.67	0.673
TYROBP	-0.35	0.212	-0.56	0.012	-0.84	0.000	ZNF817	0.27	0.108	0.95	0.008	0.67	0.673
USMG5	-0.39	0.120	-0.49	0.018	-0.68	0.001	ZNF818	0.27	0.108	0.95	0.008	0.67	0.673
USP19	0.46	0.145	0.76	0.005	0.64	0.044	ZNF819	0.27	0.108	0.95	0.008	0.67	0.673
USP38	0.44	0.105	0.49	0.029	0.61	0.006	ZNF820	0.27	0.108	0.95	0.008	0.67	0.673
XYLT2	0.27	0.329	0.60	0.005	0.57	0.006	ZNF821	0.27	0.108	0.95	0.008	0.67	0.673
ACTR5	0.56	0.137	0.74	0.018	0.53	0.093	ZNF822	0.27	0.108	0.95	0.008	0.67	0.673
ADAMDEC1	-0.88	0.095	-1.24	0.004	-0.63	0.176	ZNF823	0.27	0.108	0.95	0.008	0.67	0.673
ARHGAP18	-0.55	0.086	-0.63	0.021	-0.51	0.080	ZNF824	0.27	0.108	0.95	0.008	0.67	0.673
AUH	1.01	0.101	1.14	0.026	0.67	0.223	ZNF825	0.27	0.108	0.95	0.008	0.67	0.673
BAG2	0.29	0.548	0.70	0.042	0.42	0.254	ZNF826	0.27	0.108	0.95	0.008	0.67	0.673
BAIAP2	-0.44	0.367	-0.82	0.031	-0.32	0.474	ZNF827	0.27	0.108	0.95	0.008	0.67	0.673
BLOC1S3	-0.54	0.180	-0.71	0.029	-0.37	0.290	ZNF828	0.27	0.108	0.95	0.008	0.67	0.673
C16orf54	0.40	0.128	0.52	0.008	0.30	0.177	ZNF829	0.27	0.108	0.95	0.008	0.67	0.673
C1orf216	0.25	0.669	0.82	0.042	0.55	0.193	ZNF830	0.27	0.108	0.95	0.008	0.67	0.673
C2orf49	-0.47	0.455	-0.97	0.040	-0.44	0.407	ZNF831	0.27	0.108	0.95	0.008	0.67	0.673
C3orf58	0.46	0.128	0.60	0.032	0.43	0.144	ZNF832	0.27	0.108	0.95	0.008	0.67	0.673
CANX1D	0.47	0.282	0.64	0.040	0.48	0.136	ZNF833	0.27	0.108	0.95	0.008	0.67	0.673
CC12	-0.33	0.522	-0.86	0.019	-0.52	0.186	ZNF834	0.27	0.108	0.95	0.008	0.67	0.673
CC17	-0.48	0.282	-0.80	0.010	-0.36	0.355	ZNF835	0.27	0.108	0.95	0.008	0.67	0.673
CCR12	-0.42	0.263	-0.76	0.011	-0.09	0.848	ZNF836	0.27	0.108	0.95	0.008	0.67	0.673
CD33	-1.08	0.261	-1.61	0.039	-1.28	0.103	ZNF837	0.27	0.108	0.95	0.008	0.67	0.673
CD6	-0.12	0.833	0.67	0.042	0.51	0.134	ZNF838	0.27	0.108	0.95	0.008	0.67	0.673
CD68	-0.35	0.184	-0.66	0.002	-0.36	0.093	ZNF839	0.27	0.108	0.95	0.008	0.67	0.673
CDCA2EP2	-0.30	0.490	-0.66	0.037	-0.08	0.864	ZNF840	0.27	0.108	0.95	0.008	0.67	0.673
CLEC4E	-0.61	0.086	-0.94	0.001	-0.53	0.069	ZNF841	0.27	0.108	0.95	0.008	0.67	0.673
CLEC7A	-0.35	0.521	-0.83	0.034	-0.51	0.223	ZNF842	0.27	0.108	0.95	0.008	0.67	0.673
CPM8	-0.52	0.422	-1.02	0.036	-0.32	0.601	ZNF843	0.27	0.108	0.95	0.008	0.67	0.673
CSF3	-0.52	0.359	-0.83	0.030	-0.51	0.160	ZNF844	0.27	0.108	0.95	0.008	0.67	0.673
CTSF	0.32	0.628	1.25	0.006	0.88	0.051	ZNF845	0.27	0.108	0.95	0.008	0.67	0.673
DAB2	-0.62	0.089	-0.67	0.029	-0.49	0.119	ZNF846	0.27	0.108	0.95	0.008	0.67	0.673
DFNA5	-0.63	0.080	-0.89	0.002	-0.33	0.311	ZNF847	0.27	0.108	0.95	0.008	0.67	0.673
EC11	0.62	0.167	0.78	0.031	0.45	0.249	ZNF848	0.27	0.108	0.95	0.008	0.67	0.673
ELAVL1	0.43	0.120	0.74	0.013	0.51	0.091	ZNF849	0.27	0.108	0.95	0.008	0.67	0.673
ERD11	-0.52	0.086	-0.85	0.001	-0.31	0.252	ZNF850	0.27	0.108	0.95	0.008	0.67	0.673
EXOSC4	-0.51	0.130	-0.69	0.013	-0.23	0.491	ZNF851	0.27	0.108	0.95	0.008	0.67	0.673
FAM105A	0.50	0.080	0.76	0.001	0.44	0.064	ZNF852	0.27	0.108	0.95	0.008	0.67	0.673
FAM83G	0.39	0.431	0.82	0.029	0.71	0.055	ZNF853	0.27	0.108	0.95	0.008	0.67	0.673
FCAR	-0.52	0.280	-0.91	0.002	-0.31	0.211	ZNF854	0.27	0.108	0.95	0.008	0.67	0.673
FCR	-0.41	0.067	-0.67	0.000	-0.27	0.169	ZNF855	0.27	0.108	0.95	0.008	0.67	0.673
HL3	0.57	0.180	0.72	0.035	0.24	0.572	ZNF856	0.27	0.108	0.95	0.008	0.67	0.673
KFBP8	0.39	0.166	0.68	0.002	0.28	0.250	ZNF857	0.27	0.108	0.95	0.008	0.67	0.673
FL11	0.63	0.053	1.03	0.000	0.51	0.065	ZNF858	0.27	0.108	0.95	0.008	0.67	0.673
FRS2	-0.36	0.529	-0.88	0.002	-0.11	0.807	ZNF859	0.27	0.108	0.95	0.008	0.67	0.673
GSD2	-0.40	0.231	-0.65	0.015	-0.02	0.973	ZNF860	0.27	0.108	0.95	0.008	0.67	0.673
GMIN2	-0.13	0.855	-0.85	0.041	-0.38	0.420	ZNF861	0.27	0.108	0.95	0.008	0.67	0.673
GGH	-0.45	0.302	-0.73	0.034	-0.59	0.091	ZNF862	0.27	0.108	0.95	0.008	0.67	0.673
GIMAP1	0.39	0.266	0.69	0.012	0.47	0.097	ZNF863	0.27	0.108	0.95	0.008	0.67	0.673
GIMAP1-GIMAP5	1.89	0.075	1.77	0.047	0.85	0.331	ZNF864	0.27	0.108	0.95	0.008	0.67	0.673
GN10	-0.30	0.280	-0.61	0.005	-0.10	0.752	ZNF865	0.27	0.108	0.95	0.008	0.67	0.673
GPR137B	-0.51	0.376	-0.90	0.044	-0.31	0.566	ZNF866	0.27	0.108	0.95	0.008	0.67	0.673
GPR35	-0.41	0.322	-0.70	0.031	-0.12	0.791	ZNF867	0.27	0.108	0.95	0.008	0.67	0.673
GPR84	-0.38	0.154	-0.68	0.002	0.05	0.891	ZNF868	0.27	0.108	0.95	0.008	0.67	0.673
GTF2I	0.85	0.101	1.11	0.009	0.75	0.082	ZNF869	0.27	0.108	0.95	0.008	0.67	0.673
GZMMA	0.55	0.059	0.77	0.019	0.31	0.448	ZNF870	0.27	0.108	0.95	0.008	0.67	0.673
HBEFG	-0.57	0.080	-0.76	0.004	-0.02	0.970	ZNF871	0.27	0.108	0.95	0.008	0.67	0.673
HECTD3	0.61	0.107	0.66	0.038	0.38	0.267	ZNF872	0.27	0.108	0.95	0.008	0.67	0.673
HLC5	0.46	0.310	0.80	0.024	0.59	0.105	ZNF873	0.27	0.108	0.95	0.008	0.67	0.673
HPF01	-0.50	0.145	-0.61	0.052	-0.23	0.487	ZNF874	0.27	0.108	0.95	0.008	0.67	0.673
HS6	-0.65	0.058	-0.85	0.003	-0.23	0.602	ZNF875	0.27	0.108	0.95	0.008	0.67	0.673
IL19	-0.62	0.543	-1.15	0.033	-0.56	0.516	ZNF876	0.27	0.108	0.95	0.008	0.67	0.673
IL1R2	-0.38	0.627	-1.20	0.025	-0.63	0.285	ZNF877	0.27	0.108	0.95	0.008	0.67	0.673
IL24	-0.86	0.053	-0.92	0.013	-0.51	0.201	ZNF878	0.27	0.108	0.95	0.008	0.67	0.673
IL8	-0.48	0.196	-0.68	0.012	-0.14	0.701	ZNF879	0.27	0.108	0.95	0.008	0.67	0.673
ILY1-AS1	-0.50	0.263	-0.76	0.035	-0.26	0.542	ZNF880	0.27	0.108	0.95	0.008	0.67	0.673
ISF3-RAB43	0.18	0.841	-1.07	0.033	0.24	0.717	ZNF881	0.27	0.108	0.95	0.008	0.67	0.673
ITB	0.24	0.621	0.73	0.030	0.33	0.372	ZNF882						

**Supplementary Table 2: List of genes significantly (FDR 5%) and differentially (fold-change > 2) expressed after incubation of human PBMCs (n=7) with IL-7 compared to unstimulated cells.**

Gene ID	logFC /Unstim	adj.P.Val	Gene ID	logFC /Unstim	adj.P.Val
CISH	3,24	1,8E-16	NOG	-1,92	1,4E-03
SOCS2	2,91	7,8E-12	MAP3K14-AS1	-1,74	1,4E-02
MEOX1	2,56	2,5E-07	S100B	-1,61	1,6E-02
DPP4	2,42	1,1E-14	PASK	-1,55	1,9E-15
BCL2	2,28	3,4E-10	TSC22D3	-1,52	1,2E-15
TAF4B	2,27	9,9E-13	TCF7	-1,43	3,2E-12
FRMD4B	1,96	5,4E-08	HPCAL4	-1,38	1,5E-04
AFAP1	1,87	4,1E-08	GIMAP2	-1,34	1,1E-12
PTGER2	1,85	1,5E-12	AVPI1	-1,32	2,7E-03
IGFBP3	1,84	9,3E-07	PF4	-1,32	2,3E-02
IRF4	1,82	5,6E-12	FAM102A	-1,13	2,1E-09
IFNG	1,66	1,4E-03	CBR3	-1,12	1,4E-03
AHR	1,64	2,3E-07	GPA33	-1,11	1,4E-03
DNLZ	1,63	1,2E-04	PHF19	-1,11	1,4E-03
CMAHP	1,57	2,8E-08	ZCCHC18	-1,10	3,7E-02
ALDH16A1	1,54	2,5E-04	IL7R	-1,10	1,4E-09
TXK	1,46	8,3E-08	CD27	-1,09	1,4E-09
ADAM19	1,46	5,8E-11	AQP3	-1,08	1,6E-04
RGS1	1,44	4,3E-09	SNHG7	-1,08	3,7E-02
PSMD3	1,44	1,8E-04	LOC100507206	-1,07	4,7E-02
CDK6	1,44	4,7E-07	TMEM204	-1,06	3,4E-10
PDE4B	1,43	1,2E-11	FAIM3	-1,03	4,4E-11
LTA	1,42	2,8E-06	NCAPH	-1,02	3,4E-04
MB21D2	1,39	1,2E-06	LY9	-1,01	6,6E-08
BHLHE40	1,39	2,5E-07	SELL	-1,00	6,4E-13
TNFRSF4	1,38	1,2E-03			
SOS1	1,37	6,1E-09			
ETS1	1,37	5,2E-05			
FAM101B	1,36	4,7E-06			
FAM13A	1,30	2,7E-04			
TAF10	1,29	4,9E-03			
CCR2	1,29	3,3E-05			
AP3M2	1,28	3,1E-09			
DDRKG1	1,28	7,0E-03			
DOHH	1,26	4,9E-02			
IKZF4	1,26	3,8E-05			
SLC4A10	1,26	5,9E-05			
KLC2	1,23	3,6E-03			
COTL1	1,23	2,9E-04			
CYLD	1,21	6,4E-13			
SYNE3	1,19	9,6E-04			
DUSP2	1,19	1,4E-02			
CD8B	1,17	1,5E-09			
ITGA4	1,16	1,2E-11			
ST3GAL5	1,15	2,8E-02			
IL2RA	1,15	1,8E-07			
GNPDA1	1,15	2,8E-09			
CCR5	1,15	2,1E-04			
MAF1	1,14	2,0E-02			
SLC37A3	1,14	1,7E-04			
SPINT1	1,14	1,8E-02			
FKBP5	1,14	2,7E-07			
DDI2	1,13	2,9E-03			
HSBP1L1	1,12	3,8E-03			
MTA2	1,12	5,8E-04			
UGCG	1,10	2,2E-03			
TLR1	1,10	5,2E-05			
C17orf59	1,07	1,4E-02			
RNF149	1,07	5,3E-05			
GNA15	1,07	7,9E-04			
POLRMT	1,06	5,3E-05			
HSPA1L	1,06	4,2E-03			
CMTM6	1,04	7,3E-13			
TRPC4AP	1,03	2,9E-04			
PITRM1	1,03	2,5E-07			
B3GNT2	1,03	1,1E-02			
KLF7	1,02	5,7E-05			
TAZ	1,01	3,2E-02			